TransCanada Establishes At-The-Market Equity Program

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
114
TransCanada Establishes At-The-Market Equity Program

CALGARY, ALBERTA--(Marketwired - June 26, 2017) - News Release - TransCanada Corporation (TSX:TRP) (NYSE:TRP) (TransCanada or Company) today announced that it has established an at-the-market equity program (ATM Program) that allows the Company to issue common shares from treasury (Common Shares) having an aggregate gross sales price of up to $1.0 billion or its U.S. equivalent, to the public from time to time, at the Company's discretion, at the prevailing market price when issued on the Toronto Stock Exchange (TSX), the New York Stock Exchange (NYSE) or on any other existing trading market for the Common Shares in Canada or the United States. The ATM Program, which is effective for a 25-month period, will be activated at the Company's discretion if and as required based on the spend profile of TransCanada's capital program and relative cost of other funding options.

Sales of the Common Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated June 26, 2017 (Equity Distribution Agreement) with TD Securities Inc., TD Securities (USA) LLC, BMO Nesbitt Burns Inc., BMO Capital Markets Corp., J.P. Morgan Securities Canada Inc. and J.P. Morgan Securities LLC (collectively, the Agents).

Sales of Common Shares will be made through "at-the-market distributions" as defined in National Instrument 44-102 - Shelf Distributions on the TSX, the NYSE or on any other existing trading market for the Common Shares in Canada or the United States. The Common Shares will be distributed at the prevailing market prices at the time of the sale and, as a result, prices may vary among purchasers and during the period of distribution. The ATM Offering is being made pursuant to a prospectus supplement dated June 26, 2017 to the Company's Canadian short form base shelf prospectus and U.S. shelf registration statement on Form F-10, each dated June 23, 2017. The Canadian prospectus supplement together with the base shelf prospectus are available on the SEDAR website at www.sedar.com . The U.S. prospectus supplement together with the U.S. base shelf prospectus and the Registration Statement will be available on EDGAR at www.sec.gov . Alternatively, the Agents will send the Canadian or U.S. prospectus supplement (together with the applicable base shelf prospectus) upon request by contacting (i) in Canada, from TD Securities Inc., email: sdcconfirms@td.com , telephone: 289-360-2009, or (ii) in the United States, from TD Securities (USA) LLC, telephone: 212-827-7392, and from BMO Capital Markets, Brampton Distribution Centre C/O The Data Group of Companies, 9195 Torbram Road, Brampton, Ontario, L6S 6H2, telephone: 905-791-3151 Ext 4312, email: torbramwarehouse@datagroup.ca , and from J.P. Morgan, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 866-803-9204, email: prospectus-eq_fi@jpmchase.com .

This news release shall not in any circumstances constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to the registration or qualification under the applicable securities laws of any jurisdiction.

With more than 65 years' experience, TransCanada is a leader in the responsible development and reliable operation of North American energy infrastructure including natural gas and liquids pipelines, power generation and gas storage facilities. TransCanada operates one of the largest natural gas transmission networks that extends more than 91,500 kilometres (56,900 miles), tapping into virtually all major gas supply basins in North America. TransCanada is the continent's leading provider of gas storage and related services with 653 billion cubic feet of storage capacity. A large independent power producer, TransCanada currently owns or has interests in approximately 6,200 megawatts of power generation in Canada and the United States. TransCanada is also the developer and operator of one of North America's leading liquids pipeline systems that extends over 4,300 kilometres (2,700 miles), connecting growing continental oil supplies to key markets and refineries. TransCanada's common shares trade on the Toronto and New York stock exchanges under the symbol TRP.

FORWARD LOOKING INFORMATION

This publication contains certain information that is forward-looking and is subject to important risks and uncertainties (such statements are usually accompanied by words such as "anticipate", "expect", "believe", "may", "will", "should", "estimate", "intend" or other similar words). Forward-looking statements in this document are intended to provide TransCanada security holders and potential investors with information regarding TransCanada and its subsidiaries, including management's assessment of TransCanada's and its subsidiaries' future plans and financial outlook. All forward-looking statements reflect TransCanada's beliefs and assumptions based on information available at the time the statements were made and as such are not guarantees of future performance. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this news release, and not to use future-oriented information or financial outlooks for anything other than their intended purpose. TransCanada undertakes no obligation to update or revise any forward-looking information except as required by law. For additional information on the assumptions made, and the risks and uncertainties which could cause actual results to differ from the anticipated results, refer to the Quarterly Report to Shareholders dated May 4, 2017 and 2016 Annual Report filed under TransCanada's profile on SEDAR at www.sedar.com and with the U.S. Securities and Exchange Commission at www.sec.gov .

Media Enquiries: Mark Cooper / James Millar 403.920.7859 or 800.608.7859 TransCanada Investor & Analyst Enquiries: David Moneta / Stuart Kampel 403.920.7911 or 800.361.6522
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading